April 17–22, 2026 · San Diego · 2418 items
← Platform layer: molecular glues, spatial omics, AI
5 people · 5 posts
Heat now 0·Peak in the comparable set 1 (Oct 2 01:00)·Change over 24h in the comparable set –·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.
| Drug / trial | Readout | Setting |
|---|---|---|
| FHD-909 / MRT-55811 / MR-2088FHD-909MR-2088MRT-55811 | Epigenetic / ULK tool molecules on the floor | Platform layer, not viral threads |
Foghorn Therapeutics is cutting 40% of its staff after FHD-909, a cancer drug developed with Eli Lilly, failed to meet efficacy benchmarks. The company is discontinuing that program and a SMARCA2-targeted drug, ending its collaboration with Lilly, which began in 2021. Shares fell 22% on the day.
Foghorn Therapeutics is laying off about 40% of its staff, leaving roughly 65 employees, after its collaboration with Eli Lilly collapsed. Per Foghorn's 8-K dated 2026-10-01, the partners decided not to advance the SMARCA2 inhibitor FHD-909 (LY4050784) into expansion cohorts after disappointing Phase 1 dose-escalation data, and also ended work on a selective SMARCA2 degrader programme. The cuts extend Foghorn's cash runway into the second half of 2029; its shares fell about 40–49% on the day.
Foghorn Therapeutics and Eli Lilly ended their oncology collaboration after Phase 1 data on cancer candidate FHD-909 (LY4050784) showed insufficient efficacy, halting its move into clinical development expansion and a SMARCA2 degrader program. Foghorn is cutting about 40% of its workforce, leaving roughly 65 full-time employees, and will refocus on its proprietary programs including EP300 and CBP degraders. The 2021 deal had brought $300 million upfront plus an $80 million equity investment from Lilly's Loxo Oncology, and the changes should extend Foghorn's cash runway into the second half of 2029.
Why it matters: A terminated big-pharma oncology alliance triggers pipeline reprioritization, layoffs and a readout on the SMARCA2 synthetic lethality hypothesis.